我不是韭菜花
2021-08-24
黑心商
PharmaCyte stock loses half its value, after tripling in two days led to relatively large stock offering
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":834532993,"tweetId":"834532993","gmtCreate":1629812716412,"gmtModify":1631886413173,"author":{"id":3575032440652043,"authorId":3575032440652043,"authorIdStr":"3575032440652043","name":"我不是韭菜花","avatar":"https://static.tigerbbs.com/29371913e25e476e16139cd75ba52a41","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>黑心商</p></body></html>","htmlText":"<html><head></head><body><p>黑心商</p></body></html>","text":"黑心商","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/834532993","repostId":2160764638,"repostType":2,"repost":{"id":"2160764638","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1629375960,"share":"https://www.laohu8.com/m/news/2160764638?lang=&edition=full","pubTime":"2021-08-19 20:26","market":"us","language":"en","title":"PharmaCyte stock loses half its value, after tripling in two days led to relatively large stock offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2160764638","media":"Dow Jones","summary":"MW PharmaCyte stock loses half its value, after tripling in two days led to relatively large stock o","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW PharmaCyte stock loses half its value, after tripling in two days led to relatively large stock offering\n</p>\n<p>\n Shares of PharmaCyte Biotech Inc. <a href=\"https://laohu8.com/S/PMCB\">$(PMCB)$</a> lost more than half their value in premarket trading Thursday, after the biotechnology company took advantage of a more than tripling in its stock price over the past two days to sell a relatively large amount of shares. The company said it entered into agreement with institutional investors for a direct offering of of 14.0 million shares priced at-the-market. The effective price of the offering was $5.00 a share, which is 49.5% below Wednesday's closing price of $9.90, as the company raised $70 million. The company had 1.61 million shares outstanding as of Aug. 9. The company also issued to the investors warrants to buy up to 7.0 million shares of common stock. The stock plunged 58.5% in premarket trading Thursday, after rocketing 234.5% over the past two days, after the company said it moved to a Nasdaq listing after previously trading over the counter. \n</p>\n<p>\n -Tomi Kilgore \n</p>\n<pre>\n \n</pre>\n<p>\n <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n August 19, 2021 08:26 ET (12:26 GMT)\n</p>\n<p>\n Copyright (c) 2021 Dow Jones & Company, Inc.\n</p>\n</font></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PharmaCyte stock loses half its value, after tripling in two days led to relatively large stock offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharmaCyte stock loses half its value, after tripling in two days led to relatively large stock offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-08-19 20:26</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW PharmaCyte stock loses half its value, after tripling in two days led to relatively large stock offering\n</p>\n<p>\n Shares of PharmaCyte Biotech Inc. <a href=\"https://laohu8.com/S/PMCB\">$(PMCB)$</a> lost more than half their value in premarket trading Thursday, after the biotechnology company took advantage of a more than tripling in its stock price over the past two days to sell a relatively large amount of shares. The company said it entered into agreement with institutional investors for a direct offering of of 14.0 million shares priced at-the-market. The effective price of the offering was $5.00 a share, which is 49.5% below Wednesday's closing price of $9.90, as the company raised $70 million. The company had 1.61 million shares outstanding as of Aug. 9. The company also issued to the investors warrants to buy up to 7.0 million shares of common stock. The stock plunged 58.5% in premarket trading Thursday, after rocketing 234.5% over the past two days, after the company said it moved to a Nasdaq listing after previously trading over the counter. \n</p>\n<p>\n -Tomi Kilgore \n</p>\n<pre>\n \n</pre>\n<p>\n <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n August 19, 2021 08:26 ET (12:26 GMT)\n</p>\n<p>\n Copyright (c) 2021 Dow Jones & Company, Inc.\n</p>\n</font></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PMCB":"PharmaCyte Biotech, Inc."},"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2160764638","content_text":"MW PharmaCyte stock loses half its value, after tripling in two days led to relatively large stock offering\n\n\n Shares of PharmaCyte Biotech Inc. $(PMCB)$ lost more than half their value in premarket trading Thursday, after the biotechnology company took advantage of a more than tripling in its stock price over the past two days to sell a relatively large amount of shares. The company said it entered into agreement with institutional investors for a direct offering of of 14.0 million shares priced at-the-market. The effective price of the offering was $5.00 a share, which is 49.5% below Wednesday's closing price of $9.90, as the company raised $70 million. The company had 1.61 million shares outstanding as of Aug. 9. The company also issued to the investors warrants to buy up to 7.0 million shares of common stock. The stock plunged 58.5% in premarket trading Thursday, after rocketing 234.5% over the past two days, after the company said it moved to a Nasdaq listing after previously trading over the counter. \n\n\n -Tomi Kilgore \n\n\n \n\n\n$(END)$ Dow Jones Newswires\n\n\n August 19, 2021 08:26 ET (12:26 GMT)\n\n\n Copyright (c) 2021 Dow Jones & Company, Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":353,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/834532993"}
精彩评论